pCDCAR1 CD19 h(4ζ), NK(CAR-NK-2-M328-4Z)
The vector of anti-CD19 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CD19. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to CD4 transmembrane domain and CD3-zeta signaling domains. And the vector product was designed for the treatment of chronic lymphocytic leukemia (CLL).
Targeting Cell Type
Chronic lymphocytic leukemia (CLL)
Discription of Signaling Cassetes
Cluster of Differentiation 4 (CD4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages and dendritic cells, and plays an important role in the development and activation of T cells. On T cells, CD4 is the co-receptor for the T cell receptor (TCR), and these two distinct structures recognize the Antigen-Major Histocompatibility Complex (MHC). CD4 signaling in CAR ensures specificity of the TCR-antigen interaction, prolongs the contact between the T cell and the antigen presenting cell and recruits the tyrosine kinase Lck, which is essential for T cell activation.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 (4G7) h(CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CD19 (FMC-63) h(2B4-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-OX40-CD3ζ, SJ25C1) Viral Particle
||Anti-CD19 (Denintuzumab) scFv h(CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 105976) Viral Particle
||Anti-CD19 scFv h(CD28-OX40-CD3ζ) CARNK, pCDCAR1
||Anti-CD19 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1
||Anti-CD19 h(CD2-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (SJ25C1) h(CD28-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD28-CD3ζ, SJ25C1) Viral Particle